ANTIBODIES AGAINST ROR1 AND USES THEREOF

Disclosed herein are monoclonal antibodies against ROR1, bispecific antibodies against ROR1 and CD3, nucleic acids comprising the antibodies, vectors comprising the nucleic acids, and host cell comprising the nucleic acids or the vectors. Also disclosed are pharmaceutical compositions and antibody-d...

Full description

Saved in:
Bibliographic Details
Main Authors WANG, Guannv, XIAO, Zuoxiang, PENG, Jiaping, ZHOU, Dongwen, ZHOU, Wei, MIAO, Hangbin
Format Patent
LanguageEnglish
French
Published 26.01.2023
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:Disclosed herein are monoclonal antibodies against ROR1, bispecific antibodies against ROR1 and CD3, nucleic acids comprising the antibodies, vectors comprising the nucleic acids, and host cell comprising the nucleic acids or the vectors. Also disclosed are pharmaceutical compositions and antibody-drug conjugates comprising the antibodies, and therapeutic methods for using the antibodies. L'invention concerne des anticorps monoclonaux contre ROR1, des anticorps bispécifiques contre ROR1 et CD3, des acides nucléiques comprenant les anticorps, des vecteurs comprenant les acides nucléiques, et une cellule hôte comprenant les acides nucléiques ou les vecteurs. L'invention concerne également des compositions pharmaceutiques et des conjugués anticorps-médicament comprenant les anticorps, et des procédés thérapeutiques pour utiliser les anticorps.
Bibliography:Application Number: WO2022CN93348